xml version="1.0" encoding="utf-8" ?   8-K   

   ELI LILLY & Co false 0000059478        0000059478   2022-01-31 2022-01-31     0000059478  us-gaap:CommonStockMember    2022-01-31 2022-01-31     0000059478  lly:M1.000NotesDue20228Member    2022-01-31 2022-01-31     0000059478  lly:M718NotesDue20251Member    2022-01-31 2022-01-31     0000059478  lly:M1.625NotesDue20262Member    2022-01-31 2022-01-31     0000059478  lly:M2.125NotesDue20303Member    2022-01-31 2022-01-31     0000059478  lly:M0.625NotesDue20314Member    2022-01-31 2022-01-31     0000059478  lly:M0.500NotesDue20335Member    2022-01-31 2022-01-31     0000059478  lly:M6.77NotesDue20366Member    2022-01-31 2022-01-31     0000059478  lly:A1625NotesDue2043Member    2022-01-31 2022-01-31     0000059478  lly:M1.700NotesDue20497Member    2022-01-31 2022-01-31     0000059478  lly:A1125NotesDue2051Member    2022-01-31 2022-01-31     0000059478  lly:A1375NotesDue2061Member    2022-01-31 2022-01-31      

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION 

Washington, D.C. 20549 

FORM 8-K 

CURRENT REPORT 

Pursuant to Section 13 or 15(d) 

of the Securities Exchange Act of 1934 

Date of Report (Date of Earliest Event Reported): January 31, 2022 

 ELI LILLY AND COMPANY  

(Exact Name of Registrant as Specified in its Charter) 

  [DATA_TABLE_REMOVED] 

  [DATA_TABLE_REMOVED] 

Registrant’s Telephone Number, Including Area Code: (317) 276-2000 

Not Applicable 

(Former Name or Former Address, if Changed Since Last Report.) 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.): 

 ☐  

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

 ☐  

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

 ☐  

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

 ☐  

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

Securities registered pursuant to Section 12(b) of the Act: 

  [DATA_TABLE_REMOVED] 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). 

Emerging growth company ☐ 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 

 Item 8.01  

Other Events.  

On January 31, 2022, Eli Lilly and Company (the “Company”) issued a notice for the redemption of all €600,000,000 aggregate principal amount outstanding of its 1.000% Notes due 2022 (the “Notes”). The Notes will be redeemed in full on March 2, 2022 (the “Redemption Date”) at a redemption price equal to 100% of the principal amount thereof, plus accrued and unpaid interest thereon, if any, to, but excluding, the Redemption Date. The notice of redemption specifying the terms and procedures for the redemption is being delivered to holders of the Notes at the Company’s direction by Deutsche Bank Trust Company Americas, located at Winchester House, 1 Great Winchester Street, London EC2N 2DB, United Kingdom, as trustee for the Notes. This Current Report on Form 8-K does not constitute a notice of redemption for the Notes.   

SIGNATURES  

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.  

 [DATA_TABLE_REMOVED]